Symbol
| AGR2
| contributors: mct - updated : 11-01-2012
|
HGNC name
| anterior gradient 2 homolog (Xenopus laevis)
|
HGNC id
| 328
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in early stage mucinous ovarian tumors compared to normal ovarian tissues and serous type ovarian tumors  | tumoral
|  
|  
| --over
|  
|
in prostate cancer compared to non-malignant cells, but relatively lower levels of AGR2 are highly predictive of disease recurrence following radical prostatectomy  | tumoral
|  
|  
| --over
|  
|
in breast cancer  | |
Susceptibility
|
to ulcerative colitis |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| potential biomarker for the diagnosis of mucinous ovarian cancer  | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | reproductive | breast |  |
utility of anti-AGR2 therapy in ER-positive breast cancers because of its impact on cancer-relevant pathways | cancer | digestive | pancreas |  |
may be a useful molecular target in pancreatic cancer |
| | |
| mice lacking Agr2 were viable but were highly susceptible to colitis, indicating a critical role for Agr2 in protection from disease  |